Showing results (11-20 of 20) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Cancer|July 15, 1993
Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine-activated killer cell function in patients with breast cancerC N Baxevanis, G J Reclos, A D Gritzapis, et al.Clinical and Experimental Immunology|November 1, 1987
Multiple sclerosis: II. Effects of prothymosin alpha on the autologous and allogeneic MLR in patients with multiple sclerosisG J Reclos, C N Baxevanis, C Sfagos, et al.Journal of Neuroimmunology|May 1, 1989
Decreased expression of HLA-DR antigens on monocytes in patients with multiple sclerosisC N Baxevanis, G J Reclos, P Arsenis, et al.Journal of Immunology (Baltimore, Md. : 1950)|April 1, 1992
Prothymosin alpha enhances human and murine MHC class II surface antigen expression and messenger RNA accumulationC N Baxevanis, D Thanos, G J Reclos, et al.Immunopharmacology and Immunotoxicology|January 1, 1990
Enhancement of human T lymphocyte function by prothymosin alpha: increased production of interleukin-2 and expression of interleukin-2 receptors in normal human peripheral blood T lymphocytesC N Baxevanis, S Frillingos, K Seferiadis, et al.Immunopharmacology and Immunotoxicology|January 1, 1988
Mechanism of action of prothymosin alpha in the human autologous mixed lymphocyte responseC N Baxevanis, G J Reclos, M Economou, et al.Mutation Research|November 16, 1992
Sister-chromatid exchange in highly purified human CD4+ and CD8+ lymphocytesC Sarri, C N Baxevanis, G B Côté, et al.Journal of Neuroimmunology|March 1, 1989
Peptides of myelin basic protein stimulate T lymphocytes from patients with multiple sclerosisC N Baxevanis, G J Reclos, C Servis, et al.Anticancer Research|March 1, 1992
Monocyte disorders associated with T cell defects in patients with solid tumorsE Anastasopoulos, G J Reclos, C N Baxevanis, et al.Natural Immunity|January 1, 1993
Comparison of immune parameters in patients with one or two primary malignant neoplasmsC N Baxevanis, G J Reclos, A D Gritzapis, et al.Pageof 2